G8 Countries Generics Market Summary, Competitive Analysis and Forecast to 2027


Summary

The G8 Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2018-22, and forecast to 2027). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.


Key Highlights

  • G8 countries contributed $149,123.6 million in 2022 to the global generics industry, with a compound annual growth rate (CAGR) of 5.3% between 2018 and 2022. The G8 countries are expected to reach a value of $194,881.1 million in 2027, with a CAGR of 5.5% over the 2022-27 period.
  • Among the G8 nations, the US is the leading country in the generics industry, with market revenues of $69,916.7 million in 2022. This was followed by Germany and the UK, with a value of $25,152.7 and $15,416.4 million, respectively.
  • The US is expected to lead the generics industry in the G8 nations with a value of $82,184.5 million in 2016, followed by Germany and the UK with expected values of $33,999.8 and $23,214.8 million, respectively.




Scope

  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the G8 generics market
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the G8 generics market
  • Leading company profiles reveal details of key generics market players’ G8 operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the G8 generics market with five year forecasts by both value and volume
  • Compares data from the US, Canada, Germany, France, UK, Italy, Russia and Japan, alongside individual chapters on each country




Reasons To Buy

  • What was the size of the G8 generics market by value in 2022?
  • What will be the size of the G8 generics market in 2027?
  • What factors are affecting the strength of competition in the G8 generics market?
  • How has the market performed over the last five years?
  • How large is the G8 generics market in relation to its regional counterparts?